SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong Q3 results and outlook for expanding its AI-compute business, reinforced by a wave of analyst upgrades, are driving the rally. Bulls also point to possible Tesla merger discussions, while skeptics question the valuation and capital spending and flag a major share unlock as a potential source of selling pressure.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives upsized SATS preferred-stock offering and its use to finance further Bitcoin accumulation are driving discussion, alongside reports of additional BTC purchases. Bulls see the preferred funding and growing treasury as supportive, while skeptics warn that the high dividend obligations and senior claims could weigh on common shareholders.

Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 is headquartered in New York, NY.

Skydance Corp. - Ordinary Shares - Class B

Skydances distribution of separately traded warrants has dominated discussion, as the shares fell sharply on the ex-warrant date and many traders debated how much of the move reflected the mechanical separation versus additional selling and confusion over broker handling. Reactions are split between holders who view the combined shares-and-warrants value as largely intact and skeptics focused on the companys heavy debt and dilution risk.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares are under pressure after softer next-quarter guidance and a reduced advertising outlook overshadowed an earnings beat, with analyst downgrades and target cuts adding to concerns about slowing growth and competition. Traders are divided between viewing the selloff as an overreaction and buying the dip, or expecting further weakness amid doubts about the companys growth prospects.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEPs steep decline and new lows are driving discussion, with investors questioning the sustainability of its distribution amid losses, dilution and concerns about Icahn Enterprises performance. Bulls point to the value of its CVR Energy stake and high short interest as potential supports, while skeptics argue those factors have yet to offset the partnerships broader weakness.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JDs quarterly results and the sharp selloff that followed dominate discussion, despite some traders viewing profitability and cash-flow trends as encouraging. The debate centers on whether weaker revenue reflects soft Chinese consumer demand and justifies the decline, or whether the market is overlooking improving margins and shareholder returns.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly earnings are the main focus, especially whether AI spending will keep rising and whether Muse and AI investments can support growth. Bullish traders expect strong AI and advertising momentum, while skeptics worry about heavy capital spending, pressure on cash flow, and a negative reaction even if results are solid.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

A fatal rider accident at Six Flags Over Georgia, followed by precautionary coaster closures as the investigation continues, is driving concern about safety, attendance and potential legal exposure. Traders are also weighing analyst target cuts and the companys heavy debt against hopes the incidents impact will fade and the business can recover.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds quarterly results and sharply weaker fourth-quarter profit outlook have put fuel costs and margin pressure at the center of the discussion, despite record revenue and resilient travel demand. Traders are split between seeing the share rebound as evidence of buying support and worrying that elevated jet-fuel costs will keep weighing on profits.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its upcoming earnings report after a prolonged selloff in semiconductor-equipment stocks. Traders are split between buying the pullback on expectations for strong AI- and memory-driven demand and worrying that high expectations, guidance, and weak technical momentum could keep shares under pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine

Human clinical development is putting one of aging biology’s most closely watched proteins on the biotechnology radar   New York, NY – September 30, 2026 – Klotho is quickly becoming one of the more interesting names in longevity research. What started largely as a research question around aging and biological decline is now moving closer […]
The post Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine appeared first on Financial News Media.

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?

Equity

BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.


Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?

Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation...

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets PR Newswire NEW YORK, May 20, 2026 Cell therapies and precision biologics are driving new...

A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach

A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a...

BioAge Labs (NASDAQ:BIOA) Trading 8.6% Higher   - Here's Why

BioAge Labs (NASDAQ:BIOA) Shares Up 8.6% - What's Next...

Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell

Wall Street Zen downgraded BioAge Labs from a "hold" rating to a "sell" rating in a research report on Saturday...

BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile

BioAge Labs (NASDAQ:BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, highlighting what the company characterized as deep reductions in inflammatory...

Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?

Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

BioAge Labs Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS.</li><li>The result raised questions about whether targeting inflammation can meaningfully protect the heart, pressuring companies with related programs. &nbsp;</li><li>While BioAge’s BGE-102 is in mid-stage trials, MRT-8102 is in an early-stage study. &nbsp;</li></ul>Shares of BioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) plunged on Friday after Novo Nordisk’s (NVO) late-stage trial setback raised concerns about biotech stocks pursuing similar approaches to treating heart disease through inflammation reduction. &nbsp;BIOA tumbled 64%, while GLUE dropped about 27%. BIOA clocked its worst day since December 2024, while GLUE booked its worst day ever.<h2 class="st-heading-2">NVO’s Trial Miss</h2>Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS. The once-monthly treatment was designed to lower the risk of heart attacks, strokes, and related deaths in patients with heart and kidney problems plus high inflammation. While the drug successfully reduced inflammation markers as expected, it showed no benefit in cutting those major heart events compared with a placebo. The study involved more than 6,300 patients.Novo said the miss will not change its 2026 profit outlook and that two other trials of the same drug will continue. NVO shares closed 9% lower on Friday.The result also raised questions about whether targeting inflammation this way can meaningfully protect the heart, pressuring companies with related programs such as BioAge and Monte Rosa. While BioAge’s BGE-102 is in mid-stage trials, MRT-8102 is in an early-stage study. &nbsp;<h2 class="st-heading-2">Wall Street Weighs In</h2>Analysts weighed in on BioAge, whose lead candidate BGE-102 targets a similar approach as ziltivekimab. Jefferies cut its price target to $21 from $62 but kept a Buy rating, saying the “outright” failure raises biological risk for a key inflammation marker as a heart-risk signal. The firm still sees potential differentiation for BGE-102, but called its profile harder to predict now.Citi noted BIOA’s greater-than-60% drop and agreed the data is a negative for BioAge’s heart-disease thesis, yet argued the size of the move “seems overdone” with the company’s enterprise value nearing zero. Citi maintains a Buy rating and $52 price target.Roth Capital’s Adam Walsh lowered his price target to $25 from $36 while keeping a Buy rating. The firm now sees lower chances that a partner will fund a heart trial for BGE-102 or that it will succeed, but its estimates for the same drug in eye disease stay the same. &nbsp;The new price targets on BIOA represent a potential upside of 132% to 475% from the stock’s Friday close.Jefferies also cut its price target on Monte Rosa (GLUE) to $25 from $40, still implying a potential upside of 51% from the last close, and kept a Buy rating. Success in the ZEUS trial would have supported Monte Rosa’s approach to residual inflammation in heart disease with its experimental drug MRT-8102, so the miss is “a setback.” The firm still sees prospects in other indications and other pipeline value drivers. &nbsp;<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around BIOA improved from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high levels.’Meanwhile, sentiment around GLUE stock rose from ‘neutral’ to ‘bullish,’ accompanied by a rise in retail chatter.A Stocktwits user termed the selloff on Friday as an “oversold play” and voiced hopes for a recovery in the next few days.<stembedurl>https://www.stocktwits.com/Gemini367/message/660591844</stembedurl>While <a href="https://stocktwits.com/symbol/BIOA">BIOA stock</a> has fallen 32% year-to-date, <a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> has gained 5%.&nbsp;Read more: <a href="https://stocktwits.com/news-articles/markets/equity/tmus-stock-slips-as-300-b-deutsche-telekom-merger-talks-reportedly-hit-a-roadblock/cZN4lirRJP6">TMUS Stock Slips As $300B Deutsche Telekom Merger Talks Reportedly Hit A Roadblock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAge Labs logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS.The result raised questions about whether targeting inflammation can meaningfully protect the heart, pressuring companies with rel

Monte Rosa Therapeutics Inc

Novo Nordisk A/S

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

Meta ($META) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$5.58
Prev Close	$5.56
Open	$5.64
Dividend Yield	0.00%
50-Day Moving Average	$8.18
Beta	1.30
Avg. Volume	684,703.24
PE Ratio	-2.33

52-Week High	$25.96
52-Week Low	$4.81
Market Capitalization	$255.19M
EPS (Annual)	-$2.24
Price to Book	0.68
Revenue Per Employee	$145,080.64

Feed

News

Sentiment

Earnings

Fundamentals

Info

BIOA Fundamentals